Compare Vanguard Total International Stock Index Fund ETF (VXUS) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Total International Stock Index Fund ETF vs State Street SPDR S&P Biotech ETF — how do they compare? Vanguard Total International Stock Index Fund ETF trades at $87.94, while State Street SPDR S&P Biotech ETF trades at $159.8. Which is the better fit depends on your goals.
| VXUS | XBI | |
|---|---|---|
Sector | Sector/Thematic | Broad Market / Factor |
52-Week High | $88.41 | $169.55 |
52-Week Low | $72.17 | $93.43 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VXUS trades at $88.08, down 0.37% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF offers broad international stock exposure, excluding U.S. equities, with a low expense ratio of 0.06% as of Vanguard's latest disclosure in 2026. Recent news highlights institutional buying and long-term growth potential amid U.S. market concentration concerns.
Outlook is positive for diversification benefits and valuation discounts relative to U.S. stocks, supported by analyst optimism. Risks include foreign tax credit limitations in IRAs and emerging market volatility. Wall Street sentiment leans bullish due to improved global growth prospects.
XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard Total International Stock Index Fund ETF
VXUS is a comprehensive, low-cost ETF that tracks the FTSE Global All Cap ex US Index, providing exposure to over 8,500 stocks in both developed and emerging markets outside the United States. It serves as a foundational building block for international diversification, allowing investors to own a market-cap-weighted slice of the entire non-U.S. investable equity universe in a single vehicle.
Read more on VXUS →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
